Novo Nordisk Pharmatech bringing advanced QUATS portfolio to CPhI Worldwide Frankfurt
News | Novo Nordisk Pharmatech A/S
OCTOBER 23, 2019
Koege, Denmark: – World-leading manufacturer of recombinant insulin and GMP Quats, Novo Nordisk Pharmatech A/S will display a strong and varied portfolio of Quaternary ammonium (QUATS at the huge CPhI Worldwide pharmaceutical trade fair in Frankfurt from November 5-7.
Novo Nordisk Pharmatech has a long association with CPhI that goes back more than a decade.
The Novo Nordisk Pharmatech team on Stand 42D32 in Hall 4.2 at Frankfurt’s Messe showground will promote its range of pharmaceutical QUATS products, including Benzalkonium chloride (BKC), Cetrimite, Strong Cetrimide and Cetrimonium Bromide (CTAB).
The team will be led by Technical Sales Manager Philip Stafford, who commented: “we will be reaching out in particular to people working in pharmaceutical companies working within formulation, purchasing/procurement, BP and Quality Assurance,.”
Mr. Stafford added. “An innovative synthesis process resulting in high levels of purity make them particularly suited for pharmaceutical applications. A proven record of efficacy against a broad spectrum of microorganisms makes our Quats very effective through a wide pH range.
Proven under ICH Q1 conditions, the products are very stable and can therefore be used in a wide range of applications such as ophthalmic, nasal sprays, topical products, oral/dental products, vaccines, medical devices, veterinary and other applications that require high purity and quality.
“Big legislative and regulatory changes are coming to the industry. There is an increase in regulatory expectations from Innovators and generics to be able to guarantee patient safety due to today’s expanding global market,” notes Mr.Stafford “therefore our our pharmaceutical Quats are manufactured in accordance with cGMP Guide ICH Q7 for Active Pharmaceutical Ingredients, the highest available standard and that we analyse according to relevant multicompendial pharmacopoeias, such as Ph.Eur., USP/NF, JP and BP, ensuring patient safety”
About Novo Nordisk Pharmatech A/S
Novo Nordisk Pharmatech A/S was established in 1949, acquired by Novo Nordisk in 1986 and has been part of the pharmaceutical group since then. Novo Nordisk Pharmatech A/S is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (quats) for the pharma and biopharmaceutical industries.
About CPhI Worldwide 2019
CPhI Worldwide is the flagship annual trade show for pharma ingredients and partner sourcing providing delegates and exhibitors opportunities to arrange face-to-face meetings with potential international pharmaceutical partners and collaborators and gain insights on latest industry trends.
Now in its 30th year, the 2019 expo is a three-day event opening November 5 at the Messe showground in Frankfurt-am-Main, Germany, which last hosted CPhI in 2017.
CPhI Worldwide 2019 includes the co-located zoned exhibitions; ICSE Outsourcing solutions, P-MEC Machinery and Equipment, FDF for finished dosage formulations, InnoPack for pharmaceutical packaging and events and the new BioProduction conference focusing on bioprocessing and manufacturing.
Together, they are expected to attract 45,000 delegates along with more than 2,500 exhibiting companies from some 160 countries.
The CPhI series is staged by leading Global B2B Events Organizer and Publisher UBM Live More information at: https://www.cphi.com/europe/
Sara Gualdoni, Product Manager, Novo Nordisk Pharmatech A/S
Tel:+45 319 959 35